menu
    • menu
    [{"orgOrder":0,"company":"TRIANA Biomedicines","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"TRIANA Biomedicines","amount2":1.55,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.55,"dosageForm":"Undisclosed","sponsorNew":"TRIANA Biomedicines \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"TRIANA Biomedicines \/ Pfizer Inc"},{"orgOrder":0,"company":"TRIANA Biomedicines","sponsor":"Ascenta Capital | Bessemer Venture Partners | Regeneron Ventures | Invus | RA Capital Management | Atlas Venture | Lightspeed Venture | Pfizer Ventures | Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series B Financing","leadProduct":"TRI-611","moa":"ALK","graph1":"Oncology","graph2":"Preclinical","graph3":"TRIANA Biomedicines","amount2":0.12,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"TRIANA Biomedicines \/ Ascenta Capital | Bessemer Venture Partners | Regeneron Ventures | Invus | RA Capital Management | Atlas Venture | Lightspeed Venture | Pfizer Ventures | Surveyor Capital","highestDevelopmentStatusID":"4","companyTruncated":"TRIANA Biomedicines \/ Ascenta Capital | Bessemer Venture Partners | Regeneron Ventures | Invus | RA Capital Management | Atlas Venture | Lightspeed Venture | Pfizer Ventures | Surveyor Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by TRIANA Biomedicines

    Menu

    TRIANA Biomedicines

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TRIANA Biomedicines

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            TRIANA Biomedicines

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TRI-611

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Ascenta Capital | Bessemer Venture Partners | Regeneron Ventures | Invus | RA Capital Management | Atlas Venture | Lightspeed Venture | Pfizer Ventures | Surveyor Capital

                            Deal Size : $120.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Triana Biomedicines Secures $120M Series B Funding for Molecular Glue Degrader Pipeline

                            Details : The Series B financing round will support the development of TRI-611 for ALK+ non-small cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 03, 2025

                            Lead Product(s) : TRI-611

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Ascenta Capital | Bessemer Venture Partners | Regeneron Ventures | Invus | RA Capital Management | Atlas Venture | Lightspeed Venture | Pfizer Ventures | Surveyor Capital

                            Deal Size : $120.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TRIANA Biomedicines

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed

                            TRIANA Biomedicines

                            U.S.A arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Pfizer Inc

                            Deal Size : $1,549.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            TRIANA and Pfizer Partner to Discover Novel Molecular Glue Degraders

                            Details : The collaboration aims to discover novel molecular glue degraders for multiple targets in several disease areas, including oncology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $49.0 million

                            October 15, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Pfizer Inc

                            Deal Size : $1,549.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth